September 8, 2014 | Israeli company Protalix Biotherapeutics experienced a spike in its share price on the TASE after reports that it can synthesize a vaccine to treat Ebola. With the recent outbreak of the deadly virus in Western Africa, and the cure of at least one US aid worker who contracted the virus using a depleting Canadian vaccine, Protalix is hopeful that they will be able to produce a similar drug swiftly and efficiently. However, according to Protalix CEO Dr. David Aviezer, the Protalix drug has no connection to the Canadian vaccine that was used to cure the aid worker, and the latter vaccine is patent protected by the World Health Organization.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments